Activity, damage and outcome in systemic vasculitis

Research output: Contribution to journalArticle

Standard

Activity, damage and outcome in systemic vasculitis. / Carruthers, David; Bacon, Paul.

In: Best Practice & Research: Clinical Rheumatology, Vol. 15, No. 2, 01.06.2001, p. 225-238.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Bibtex

@article{3e98b900a0e9400eb386794e9c7d62e4,
title = "Activity, damage and outcome in systemic vasculitis",
abstract = "Current therapy has transformed the prognosis of the systemic vasculitides from diseases that had a high acute mortality rate to chronic relapsing diseases with high rates of morbidity. This improved survival has highlighted the need for better methods of monitoring disease activity and recording the accumulation of organ damage that occurs during the course of the disease. Several clinical indices have been developed that record disease activity, damage and the extent of disease. These validated indices allow a detailed assessment of the patient's response to therapy and provide an essential tool for insuring uniformity of patient monitoring in multi-centre trials. In addition, more data are now available supporting the use of these assessment tools as prognostic and outcome criteria for clinical studies. The development, properties, application and inter-relationships of the available clinical assessment tools for patients with systemic vasculitis are reviewed in this chapter.",
author = "David Carruthers and Paul Bacon",
year = "2001",
month = jun,
day = "1",
doi = "10.1053/berh.2000.0141",
language = "English",
volume = "15",
pages = "225--238",
journal = "Best Practice & Research: Clinical Rheumatology",
issn = "1521-6942",
publisher = "Elsevier",
number = "2",

}

RIS

TY - JOUR

T1 - Activity, damage and outcome in systemic vasculitis

AU - Carruthers, David

AU - Bacon, Paul

PY - 2001/6/1

Y1 - 2001/6/1

N2 - Current therapy has transformed the prognosis of the systemic vasculitides from diseases that had a high acute mortality rate to chronic relapsing diseases with high rates of morbidity. This improved survival has highlighted the need for better methods of monitoring disease activity and recording the accumulation of organ damage that occurs during the course of the disease. Several clinical indices have been developed that record disease activity, damage and the extent of disease. These validated indices allow a detailed assessment of the patient's response to therapy and provide an essential tool for insuring uniformity of patient monitoring in multi-centre trials. In addition, more data are now available supporting the use of these assessment tools as prognostic and outcome criteria for clinical studies. The development, properties, application and inter-relationships of the available clinical assessment tools for patients with systemic vasculitis are reviewed in this chapter.

AB - Current therapy has transformed the prognosis of the systemic vasculitides from diseases that had a high acute mortality rate to chronic relapsing diseases with high rates of morbidity. This improved survival has highlighted the need for better methods of monitoring disease activity and recording the accumulation of organ damage that occurs during the course of the disease. Several clinical indices have been developed that record disease activity, damage and the extent of disease. These validated indices allow a detailed assessment of the patient's response to therapy and provide an essential tool for insuring uniformity of patient monitoring in multi-centre trials. In addition, more data are now available supporting the use of these assessment tools as prognostic and outcome criteria for clinical studies. The development, properties, application and inter-relationships of the available clinical assessment tools for patients with systemic vasculitis are reviewed in this chapter.

UR - http://www.scopus.com/inward/record.url?scp=0034988996&partnerID=8YFLogxK

U2 - 10.1053/berh.2000.0141

DO - 10.1053/berh.2000.0141

M3 - Article

C2 - 11469819

VL - 15

SP - 225

EP - 238

JO - Best Practice & Research: Clinical Rheumatology

JF - Best Practice & Research: Clinical Rheumatology

SN - 1521-6942

IS - 2

ER -